Review
Copyright ©The Author(s) 2023.
World J Gastroenterol. May 7, 2023; 29(17): 2551-2570
Published online May 7, 2023. doi: 10.3748/wjg.v29.i17.2551
Table 3 Clinical trials under investigation
Drugs
Mechanisms
Clinical trials
Anakinra and CanakinumabReduce hepatic inflammationNCT01809132[121], NCT04072822[122], NCT03775109[123]
N-acetyl cysteine, S-adenosyl methionine (SAM-E)Reduce oxidative stressNCT03069300[124], NCT00851981[125], NCT02024295[126]
DUR-928Epigenetic modulation of lipid homeostasis, inflammation, cell survival, tissue regenerationNCT03432260[127], NCT03917407[128]
Granulocyte colony stimulating growth factors, interleukin-22 and obeticholic acidBoosts liver regenerationNCT02442180[129], NCT03703674[130], NCT04066179[131], NCT02655510[132], NCT01918462[133], NCT02039219[134]
Rifaximin, zinc supplementation, bovine colostrum, probiotics, and fecal microbiota transplantTargets the gut-liver axisNCT02116556[135], NCT02485106[136], NCT01968382[137], NCT02473341[138], NCT01922895[139], NCT02335632[140], NCT02458079[141], NCT03091010[142], NCT03827772[143]